Brokerages forecast that Imperva Inc (NYSE:IMPV) will report ($0.23) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Seven analysts have issued estimates for Imperva’s earnings. Imperva reported earnings of ($0.36) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 36.1%. The business is expected to issue its next earnings report on Thursday, November 2nd.

On average, analysts expect that Imperva will report full year earnings of ($0.81) per share for the current fiscal year. For the next year, analysts expect that the company will post earnings of ($1.03) per share. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Imperva.

Imperva (NYSE:IMPV) last released its quarterly earnings data on Thursday, July 27th. The software maker reported ($0.10) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.05 by $0.15. Imperva had a negative return on equity of 5.00% and a negative net margin of 4.69%. The company had revenue of $74.44 million during the quarter, compared to analysts’ expectations of $74.30 million. During the same quarter in the prior year, the company posted ($0.23) EPS. The company’s revenue for the quarter was up 28.6% on a year-over-year basis.

IMPV has been the topic of a number of analyst reports. Stifel Nicolaus restated a “hold” rating and issued a $47.00 price target on shares of Imperva in a research note on Friday, July 14th. Susquehanna Bancshares Inc initiated coverage on Imperva in a research note on Wednesday, June 7th. They issued a “positive” rating and a $60.00 price target on the stock. UBS AG initiated coverage on Imperva in a research note on Tuesday, June 6th. They issued a “positive” rating and a $60.00 price target on the stock. Stephens restated an “overweight” rating and issued a $61.00 price target (up from $53.00) on shares of Imperva in a research note on Thursday, July 13th. Finally, BidaskClub downgraded Imperva from a “buy” rating to a “hold” rating in a research note on Tuesday, July 25th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. The stock presently has an average rating of “Buy” and an average target price of $51.25.

Imperva (NYSE:IMPV) traded up 0.11% during midday trading on Tuesday, reaching $44.00. The company’s stock had a trading volume of 475,997 shares. The stock’s 50 day moving average is $48.32 and its 200 day moving average is $45.20. The stock’s market cap is $1.48 billion. Imperva has a 12-month low of $34.40 and a 12-month high of $57.24.

TRADEMARK VIOLATION NOTICE: This piece was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/08/08/imperva-inc-nyseimpv-expected-to-announce-earnings-of-0-23-per-share.html.

In other news, SVP Sunil D. Nagdev sold 4,857 shares of the business’s stock in a transaction on Tuesday, May 16th. The stock was sold at an average price of $49.00, for a total value of $237,993.00. Following the completion of the transaction, the senior vice president now directly owns 16,290 shares of the company’s stock, valued at $798,210. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CRO Michael D. Mooney sold 52,356 shares of the business’s stock in a transaction on Wednesday, May 10th. The stock was sold at an average price of $47.51, for a total value of $2,487,433.56. Following the completion of the transaction, the executive now directly owns 52,356 shares of the company’s stock, valued at $2,487,433.56. The disclosure for this sale can be found here. Over the last three months, insiders sold 60,302 shares of company stock valued at $2,875,861. Insiders own 2.20% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in IMPV. North Run Capital LP boosted its position in Imperva by 999.3% in the first quarter. North Run Capital LP now owns 750,000 shares of the software maker’s stock worth $30,788,000 after buying an additional 681,772 shares during the period. Clearbridge Investments LLC boosted its position in Imperva by 47.0% in the first quarter. Clearbridge Investments LLC now owns 1,262,507 shares of the software maker’s stock worth $51,826,000 after buying an additional 403,809 shares during the period. BNP Paribas Arbitrage SA boosted its position in Imperva by 8,392.3% in the first quarter. BNP Paribas Arbitrage SA now owns 200,927 shares of the software maker’s stock worth $8,248,000 after buying an additional 198,561 shares during the period. Caisse DE Depot ET Placement DU Quebec bought a new position in Imperva during the first quarter worth $7,192,000. Finally, Bank of Nova Scotia bought a new position in Imperva during the first quarter worth $7,184,000. 92.72% of the stock is owned by institutional investors.

About Imperva

Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company is engaged in the development, marketing, sales, service and support of cyber-security solutions. The Company’s products include its Imperva SecureSphere Paltform, Imperva CounterBreach and Imperva Camouflage for enterprise data centers, and Imperva Incapsula offering for cloud-based security services.

Get a free copy of the Zacks research report on Imperva (IMPV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Imperva Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva Inc and related companies with MarketBeat.com's FREE daily email newsletter.